PharmaEssentia Corporation

BDL:261280523 Stock Report

Market Cap: US$6.2b

PharmaEssentia Management

Management criteria checks 3/4

PharmaEssentia's CEO is Ko-Chung Lin, appointed in Jan 2017, has a tenure of 7.92 years. directly owns 1.73% of the company’s shares, worth $106.49M. The average tenure of the management team and the board of directors is 5.2 years and 3.3 years respectively.

Key information

Ko-Chung Lin

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7.9yrs
CEO ownership1.7%
Management average tenure5.2yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ko-Chung Lin's remuneration changed compared to PharmaEssentia's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

NT$2b

Jun 30 2024n/an/a

NT$1b

Mar 31 2024n/an/a

NT$442m

Dec 31 2023n/an/a

-NT$624m

Sep 30 2023n/an/a

-NT$890m

Jun 30 2023n/an/a

-NT$1b

Mar 31 2023n/an/a

-NT$2b

Dec 31 2022n/an/a

-NT$1b

Sep 30 2022n/an/a

-NT$2b

Jun 30 2022n/an/a

-NT$2b

Mar 31 2022n/an/a

-NT$3b

Dec 31 2021NT$9mNT$9m

-NT$3b

Sep 30 2021n/an/a

-NT$3b

Jun 30 2021n/an/a

-NT$3b

Mar 31 2021n/an/a

-NT$2b

Dec 31 2020NT$9mNT$9m

-NT$2b

Sep 30 2020n/an/a

-NT$1b

Jun 30 2020n/an/a

-NT$862m

Mar 31 2020n/an/a

-NT$856m

Dec 31 2019NT$9mNT$8m

-NT$843m

Compensation vs Market: Insufficient data to establish whether Ko-Chung's total compensation is reasonable compared to companies of similar size in the Luxembourg market.

Compensation vs Earnings: Ko-Chung's compensation has been consistent with company performance over the past year.

CEO

Ko-Chung Lin

7.9yrs

Tenure

NT$9,389,000

Compensation

Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...

Leadership Team

NamePositionTenureCompensationOwnership
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer12.3yrsNT$8.49m1.09%
$ 67.0m
Ko-Chung Lin
Founder7.9yrsNT$9.39m1.73%
$ 106.5m
Chan-Kou Hwang
Presidentno dataNT$8.49m0.61%
$ 37.3m
Snow Chang
Accounting Manager & Senior Manager of Finance9.2yrsno datano data
Samuel Lin
VP and Head of Business Operations & Strategy2.9yrsno datano data
Lih-Ling Lin
Chief Scientific Officer2.3yrsno data0.010%
$ 630.2k
Rachel Lipsitz
VP and Head of Corporate Communications & Advocacy2.9yrsno datano data
Roddy Mcilwain
Senior VP and Head of Sales & Marketing3.9yrsno datano data
Anjana Pursnani
Senior VP & Head of People2.9yrsno datano data
Albert Qin
Chief Medical Officer7.9yrsno data0.0061%
$ 375.2k
Narihisa Miyachi
Head of Japan Medical Affairs6.4yrsno datano data
Yen-Tung Luan
Chief Operating Officer of Taichung Plant6.4yrsno datano data

5.2yrs

Average Tenure

Experienced Management: 261280523's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer12.3yrsNT$8.49m1.09%
$ 67.0m
Ko-Chung Lin
Founder3.3yrsNT$9.39m1.73%
$ 106.5m
Chan-Kou Hwang
President9.6yrsNT$8.49m0.61%
$ 37.3m
Jeffrey R. Williams
Independent Directorless than a yearno datano data
Ching-Tsun Liu
Independent Directorless than a yearno data0.13%
$ 7.8m
Jinn-Der Chang
Independent Director10.8yrsNT$120.00k0.029%
$ 1.8m
Jien-Heh Tien
Independent Director6.5yrsNT$120.00k0.00060%
$ 37.0k
Ming-Chuan Hsieh
Independent Directorless than a yearno data0.0012%
$ 73.9k
Norio Komatsu
Chairperson of Japan3.6yrsno datano data
Shen Yi Li
Director3.3yrsNT$95.00k0.24%
$ 15.0m
HsuehFang Hsu
Directorless than a yearno datano data
ChenJung Hsiao
Directorless than a yearno datano data

3.3yrs

Average Tenure

Experienced Board: 261280523's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 05:18
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaEssentia Corporation is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pinghan HsiehCapital Securities Corporation
Wangbin ZhouCitigroup Inc
Hsuan ChenKGI Securities Co. Ltd.